Adrenergic antagonists: Beta blockers

37,568views

Adrenergic antagonists: Beta blockers

Watch later

Watch later

Parathyroid hormone
Calcitonin
Vitamin D
Insulin
Glucagon
Diabetes mellitus
Diabetes mellitus: Pathology review
Pancreatic neuroendocrine neoplasms
Hyperparathyroidism
Hypoparathyroidism
Parathyroid disorders and calcium imbalance: Pathology review
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Osteoporosis medications
Hypertrophic cardiomyopathy
Pigmentation skin disorders: Pathology review
Albinism
Thymus histology
Glomerular filtration
Measuring renal plasma flow and renal blood flow
Thyroglossal duct cyst
Bowel obstruction
Platelet plug formation (primary hemostasis)
Anatomy of the abdominal viscera: Kidneys, ureters and suprarenal glands
Anatomy of the perineum
Thiazide and thiazide-like diuretics
Vaginal and vulvar disorders: Pathology review
Alpha-thalassemia
Spleen histology
Fallopian tube and uterus histology
Mammary gland histology
Ovary histology
Brucella
Oral cancer
Oxygen binding capacity and oxygen content
Obstructive lung diseases: Pathology review
Ehrlichia and Anaplasma
Myeloproliferative disorders: Pathology review
Nervous system anatomy and physiology
Hyperkalemia
Dementia: Pathology review
Anatomy of the heart
Anatomy of the coronary circulation
Anatomy clinical correlates: Heart
Anatomy clinical correlates: Mediastinum
Infectious endocarditis: Clinical sciences
Infective endocarditis: Clinical
Endocarditis
Endocarditis: Pathology review
Development of the respiratory system
Adenovirus
Anatomy of the arm
Perinatal infections: Clinical
Dyslipidemias: Pathology review
Acyanotic congenital heart defects: Pathology review
Blood pressure, blood flow, and resistance
ECG basics
Development of the cardiovascular system
Fetal circulation
Calcium channel blockers
Anatomy of the eye
Introduction to the cranial nerves
Cranial nerve pathways
Anatomy of the olfactory (CN I) and optic (CN II) nerves
Anatomy of the oculomotor (CN III), trochlear (CN IV) and abducens (CN VI) nerves
Anatomy of the trigeminal nerve (CN V)
Anatomy of the facial nerve (CN VII)
Anatomy of the vestibulocochlear nerve (CN VIII)
Anatomy of the glossopharyngeal nerve (CN IX)
Anatomy of the vagus nerve (CN X)
Anatomy of the spinal accessory (CN XI) and hypoglossal (CN XII) nerves
Anatomy clinical correlates: Facial (CN VII) and vestibulocochlear (CN VIII) nerves
Anatomy clinical correlates: Glossopharyngeal (CN IX), vagus (X), spinal accessory (CN XI) and hypoglossal (CN XII) nerves
Anatomy clinical correlates: Oculomotor (CN III), trochlear (CN IV) and abducens (CN VI) nerves
Anatomy clinical correlates: Olfactory (CN I) and optic (CN II) nerves
Anatomy clinical correlates: Trigeminal nerve (CN V)
Actinomyces israelii
Clostridium botulinum (Botulism)
Clostridium tetani (Tetanus)
Haemophilus influenzae
Listeria monocytogenes
Mycobacterium tuberculosis (Tuberculosis)
Neisseria meningitidis
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus agalactiae (Group B Strep)
Streptococcus pneumoniae
Central nervous system histology
Peripheral nervous system histology
Eye and ear histology
Coxsackievirus
Cytomegalovirus
Eastern and Western equine encephalitis virus
Epstein-Barr virus (Infectious mononucleosis)
Herpes simplex virus
JC virus (Progressive multifocal leukoencephalopathy)
Lymphocytic choriomeningitis virus
Measles virus
Mumps virus
Poliovirus
Rabies virus
Varicella zoster virus
West Nile virus
Acute disseminated encephalomyelitis
Central pontine myelinolysis
Multiple sclerosis
Transverse myelitis
Charcot-Marie-Tooth disease
Guillain-Barre syndrome
Adult brain tumors
Neurofibromatosis
Pediatric brain tumors
Pituitary adenoma
Sympathomimetics: Direct agonists
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
Cardiac muscle histology
Mesothelioma
Nasal polyps
Nasopharyngeal carcinoma
Pancoast tumor
Superior vena cava syndrome
Cystic fibrosis: Pathology review
Pleural effusion, pneumothorax, hemothorax and atelectasis: Pathology review
Pneumonia: Pathology review
Tuberculosis: Pathology review
Lung cancer and mesothelioma: Pathology review
Nasal, oral and pharyngeal diseases: Pathology review
Restrictive lung diseases: Pathology review
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Deep vein thrombosis and pulmonary embolism: Pathology review
Respiratory distress syndrome: Pathology review
Adrenergic antagonists: Presynaptic
Adrenergic receptors
Cholinergic receptors
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Sympatholytics: Alpha-2 agonists
Introduction to the immune system
Gallbladder disorders: Pathology review
Anatomy of the thyroid and parathyroid glands
Acute coronary syndrome: Clinical sciences
Approach to chest pain: Clinical sciences
Approach to dyspnea: Clinical sciences
Approach to hypertension: Clinical sciences
Coronary artery disease: Clinical sciences
Diabetes mellitus (Type 1): Clinical sciences
Diabetes mellitus (Type 2): Clinical sciences
Dyslipidemia: Clinical sciences
Essential hypertension: Clinical sciences
Tobacco use: Clinical sciences
Ketone body metabolism
Kidney histology
Ureter, bladder and urethra histology
Bladder exstrophy
Horseshoe kidney
Hydronephrosis
Hypospadias and epispadias
Potter sequence
Renal agenesis
Alport syndrome
Goodpasture syndrome
IgA nephropathy (NORD)
Lupus nephritis
Poststreptococcal glomerulonephritis
Rapidly progressive glomerulonephritis
Amyloidosis
Diabetic nephropathy
Focal segmental glomerulosclerosis (NORD)
Membranoproliferative glomerulonephritis
Membranous nephropathy
Minimal change disease
Acute tubular necrosis
Renal papillary necrosis
Acute pyelonephritis
Chronic pyelonephritis
Lower urinary tract infection
Postrenal azotemia
Prerenal azotemia
Renal azotemia
Chronic kidney disease
Kidney stones
Renal tubular acidosis
Angiomyolipoma
Medullary cystic kidney disease
Medullary sponge kidney
Multicystic dysplastic kidney
Polycystic kidney disease
Beckwith-Wiedemann syndrome
Nephroblastoma (Wilms tumor)
Non-urothelial bladder cancers
Renal cell carcinoma
Transitional cell carcinoma
WAGR syndrome
Neurogenic bladder
Posterior urethral valves
Urinary incontinence
Vesicoureteral reflux
Renal artery stenosis
Renal cortical necrosis
Metabolic acidosis
Metabolic alkalosis
Respiratory acidosis
Respiratory alkalosis
Hypercalcemia
Hypermagnesemia
Hypernatremia
Hyperphosphatemia
Hypocalcemia
Hypokalemia
Hypomagnesemia
Hyponatremia
Hypophosphatemia
Congenital renal disorders: Pathology review
Nephritic syndromes: Pathology review
Nephrotic syndromes: Pathology review
Urinary tract infections: Pathology review
Kidney stones: Pathology review
Renal failure: Pathology review
Renal tubular acidosis: Pathology review
Renal tubular defects: Pathology review
Renal and urinary tract masses: Pathology review
Urinary incontinence: Pathology review
Acid-base disturbances: Pathology review
Electrolyte disturbances: Pathology review
Appendicitis
Abdominal hernias
Inguinal hernias: Clinical sciences
Femoral hernias: Clinical sciences
Umbilical hernias: Clinical sciences
Ventral and incisional hernias: Clinical sciences
Inguinal hernia
Femoral hernia
Acute pancreatitis: Clinical sciences
Cholecystitis: Clinical sciences
Peptic ulcer disease: Clinical sciences
Anticoagulants: Warfarin
Factor V Leiden

Transcript

Watch video only

Alpha blockers and beta blockers are two types of postsynaptic anti-adrenergic medications that prevent their respective receptors from being stimulated by catecholamines, like norepinephrine and epinephrine.

The nervous system is divided into the central nervous system, so the brain and spinal cord; and the peripheral nervous system, which includes all the nerves that connect the central nervous system to the muscles and organs. The peripheral nervous system can be divided into the somatic nervous system, which controls voluntary movement of our skeletal muscles; and the autonomic nervous system, which controls the involuntary movement of the smooth muscles and glands of our organs; this system is then further divided into the sympathetic and parasympathetic nervous systems.

Now, the autonomic nervous system is made up of a relay that includes two neurons. We’ll focus on just the sympathetic nervous system. Signals for the autonomic nervous system start in the hypothalamus, at the base of the brain. Hypothalamic neurons have really long axons that carry signals all the way down to the thoracic and lumbar spinal cord nuclei, where they synapse with preganglionic neuron cell bodies. From there, the signal goes from the preganglionic neurons down its relatively short axon, exits the spinal cord, and reaches the nearby sympathetic ganglion, which is made up of lots of postganglionic neuron cell bodies. The postganglionic neurons are also called adrenergic neurons, because they release the neurotransmitter norepinephrine, which is also called noradrenalin; and to a much lesser degree, epinephrine also known as adrenaline. These two catecholamines activate the adrenergic receptors on many different organs, which allows the sympathetic nervous system to trigger the fight or flight response that increases the heart rate and blood pressure, as well as slowing down digestion. This response maximizes blood flow to the muscles and brain, and can help you either run away from a threat, or fight it, which is why it’s also called the fight or flight response.

Now, there are two main groups of adrenergic receptors: the alpha receptors, and beta receptors. Let’s focus on beta receptors, which have two main subtypes: beta1 (β1) and beta2 (β2). Beta1 adrenergic receptors are mainly located in the heart, where they increase the heart rate and contractility, which helps pump out more blood. Beta1 receptors are also found in the kidney, where they stimulate a very special kind of cell, called juxtaglomerular cells, to release renin. Renin is a part of the renin- angiotensin- aldosterone system, which increases sodium and water retention by the kidneys and helps increase blood pressure.

Moving on to beta2 adrenergic receptors, these are found on smooth muscle cells in the walls of blood vessels supplying skeletal muscles and the brain, which leads to vasodilation and increased blood flow to these tissues. In the lungs, beta2 adrenergic receptors cause bronchodilation, and that increases oxygen delivery to cells. In the gastrointestinal tract, they decrease motility and slow digestion. In the eyes, they act on the ciliary body to promote the secretion of aqueous humor, which provides support and helps to maintain the shape of the eye. Now, in the liver, they cause more glucose to be released into the blood. In the pancreatic islets of Langerhans, they promote the release of insulin. Finally, beta2 receptors stimulate an enzyme found on the surface of the cells lining capillary walls called lipoprotein lipase, which breaks down triglycerides into free fatty acids and glycerol.

Alright, so medications that act on peripheral post-synaptic adrenergic neurons to block adrenergic receptors are called peripheral post-synaptic anti-adrenergics. And based on the type of receptors they block, they are divided into two main categories - alpha blockers and beta blockers.

Now, beta blockers are subdivided into three generations. The first generation of beta blockers are non- selective blockers, meaning that they work as antagonists on both beta1 and beta2 adrenergic receptors. So, here we have propranolol, timolol, nadolol, sotalol, and pindolol. Actually, pindolol is not a pure antagonist, but a partial agonist. This means that, when bound to a beta receptor, it very weakly stimulates it, but at the same time, it prevents binding and stimulation by the more potent catecholamines. This is known as intrinsic sympathomimetic effect. Or more simply, pindolol has the same but weaker effects compared to the other first generation beta blockers.

Now, by blocking beta1 receptors in the heart, these medications decrease the heart rate and contractility, which lets the heart work less hard, and pump less blood out, resulting in a drop in its oxygen and energy demands, as well as a drop in blood pressure. At the same time, beta1 blockade in the juxtaglomerular cells in the kidney decreases renin release, which in turn decreases angiotensin II and aldosterone, letting more sodium and water be lost in the urine and lowering the blood pressure even more. Okay, but by blocking beta2 receptors as well, they also cause some vasoconstriction of blood vessels supplying the skeletal muscles and the brain. This is typically very mild though, and doesn’t have a significant effect on blood pressure. In the brain, in fact, beta2 receptors in blood vessels are only reached by propranolol, which is lipid- soluble enough to penetrate the blood- brain barrier and induce some degree of vasoconstriction.

Now, moving on to the lungs, blocking beta2 receptors causes bronchoconstriction, or narrowing of the respiratory airways, which obstructs airflow, and lets in less oxygen. In the gastrointestinal tract, beta2 blockade speeds up motility. In the eye, aqueous humor production decreases, so intraocular pressure or the pressure within the eye falls. Now in the liver, less glucose gets released in the bloodstream, and the pancreas releases less insulin. And finally, inhibition of lipoprotein lipase leads to the accumulation of triglycerides in the blood.

Alright, so looking at the indications of non- selective beta blockers, they are widely used in the treatment of hypertension; and coronary artery disease, in the form of angina pectoris or a heart attack. It has also been suggested that beta blockers slow down the progression of congestive heart failure, or CHF for short. This remains controversial though, since individuals with heart failure often rely on sympathetic drive to maintain some degree of heart function. So in this situation, beta blockers might actually make things worse, especially in a situation of acute CHF exacerbation. Next, beta blockers can be used to slow down the heart rate in cases of severe tachycardia, like in thyroid storm, which is an acute, life- threatening complication of hyperthyroidism - where the body becomes very sensitive to the effects of excess thyroid hormone. For the same reason, some people use them in cases of severe anxiety, like before giving a speech. Now propranolol in particular, has been also shown to effectively prevent migraines, a type of terrible headache, perhaps by altering blood flow to the brain. And timolol helps reduce the intraocular pressure when applied topically on the eye, which is why it’s been used in the treatment of glaucoma.

Now, side- effects of non- selective beta blockers include bradycardia and hypotension, meaning that the heart rate or blood pressure may fall too low. Note also, that in cases where someone quits taking them all of a sudden, they can lead to severe rebound tachycardia, hypertension, or even arrhythmias, meaning irregular heartbeat. There are also often complaints of fatigue, perhaps due to the reduced blood flow to the muscles, as well as dizziness, depression, insomnia, and nightmares, particularly due to the central nervous system effects of propranolol. since they can cause wheezing, shortness of breath, and chest tightness, they are also strictly contraindicated in both chronic obstructive pulmonary disease, or COPD for short; and asthma. Sometimes diarrhea has also been seen. In other cases, there’s hypertriglyceridemia, or increased blood triglycerides and hypoglycemia, or reduced blood glucose levels. Hypoglycemia is the side effect to watch out for, as it may go unnoticed, since beta blockers blunts the counter- regulatory effects and symptoms of catecholamines, like tachycardia and tremors. That’s particularly dangerous for people with diabetes, who already take a bunch of other hypoglycemic medications like insulin.

Okay, now the second generation of beta blockers are selective for beta1 adrenergic receptors, which is why they are called beta1 selective or cardioselective beta blockers. Examples here include atenolol, metoprolol, bisoprolol, esmolol, and acebutolol. Like pindolol, acebutolol is a partial beta1 receptor agonist, with an intrinsic sympathomimetic activity and weaker beta1 blocking effects.

Now, once again, by blocking beta1 receptors these medications lower blood pressure by decreasing the heart rate and contractility, while in the kidneys they decrease renin release. This makes them suitable for the treatment of hypertension, coronary artery disease, and cases of severe tachycardia, like thyroid storm and anxiety. Their use in congestive heart failure is controversial here too, but metoprolol and bisoprolol have shown fairly good results so they are commonly administered. Due to the absence of the beta2 blockade, they don’t cause bronchoconstriction, so they can be safely used in individuals with COPD and asthma. They also don’t affect blood glucose as much, so they are the preferred beta blockers for those with diabetes. Bear in mind though, that at high enough doses, these medications may also start blocking beta2 receptors, so these individuals should always be carefully monitored.

Key Takeaways

Adrenergic antagonists are a type of drug that blocks the action of adrenaline in the body. Adrenaline is a hormone that is released in response to stress or excitement, and it causes the heart rate to speed up and the blood vessels to narrow.

Beta-blockers are a type of adrenergic antagonist that blocks the sympathetic activation of Beta-adrenergic receptors. Beta-blockers work by blocking the action of adrenaline, which is responsible for the body's fight-or-flight response. This makes them ideal for treating conditions where the body's natural response to stress is harmful, such as high blood pressure and heart arrhythmia.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Chronotropic incompetence, beta-blockers, and functional capacity in advanced congestive heart failure: Time to pace?" European Journal of Heart Failure (2008)
  5. "Beta-blockers for hypertension" Cochrane Database of Systematic Reviews (2017)
  6. "Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension" Cochrane Database of Systematic Reviews (2016)
  7. "Treatment of Angina: Where Are We?" Cardiology (2018)
  8. "Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure" Clinical Research in Cardiology (2017)
  9. "A Review of Nebivolol Pharmacology and Clinical Evidence" Drugs (2015)
  10. "Management of arrhythmia in sepsis and septic shock" Anaesthesiol Intensive Ther (2017)